Logo
x

Search

Subscribe Now

Huntington Disease

uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease

uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease

  • November 3, 2021
uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease

uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease

  • May 28, 2021
uniQure Reports Completion of Enrollment in First Cohort of P- I/II Trial for AMT-130 to Treat Huntington's Disease

uniQure Reports Completion of Enrollment in First Cohort of P- I/II Trial for AMT-130 to Treat Huntington's Disease

  • April 5, 2021
Novartis's Branaplam (LMI070) Receives the US FDA's Orphan Drug Designation for Huntington's Disease

Novartis's Branaplam (LMI070) Receives the US FDA's Orphan Drug Designation for Huntington's Disease

  • October 22, 2020
uniQure Signs an Exclusive Research and License Agreement with Gen-X to Develop Novel Synthetic Promoters

uniQure Signs an Exclusive Research and License Agreement with Gen-X to Develop Novel Synthetic Promoters

  • March 3, 2020
Chugai's RG6042 Receives MHLW's Orphan Drug Designation for Huntington's Disease in Japan

Chugai's RG6042 Receives MHLW's Orphan Drug Designation for Huntington's Disease in Japan

  • February 18, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.